Array BioPharma is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company partnered drugs are binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology), and tucatinib (partnered with Cascadian Therapeutics). The company is committed to providing therapies to patients. Array BioPharma was founded on 1998 and is headquartered in Boulder, Colorado.

Patents 2,866show all

  • 748
    C07D - Heterocyclic compounds
  • 175
    A61K - Preparations for medical, dental, or toilet purposes
  • 53
    C07C - Acyclic or carbocyclic compounds
  • 37
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 31
    C07K - Peptides
  • 24
    C04B - Lime, magnesia
  • 21
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 17
    B41M - Printing, duplicating, marking, or copying processes
  • 17
    B44F - Special designs or pictures
  • 17
    G09F - Displaying

Clinical Trials 185show all

51Phase 339Phase 238Phase 136Phase 1/Phase 221N/A

SEC Filings show all


290
8-K

56
10-Q

18
10-K

2
D

1
S-1

Contact Information

3200 Walnut Street
Boulder, CO 80301
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$1,400,00051-1002016-09-17Acquired

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2016-09-17$1,400,000Post Ipo EquityRedmile Group

SEC Form D Funding Events

DateOfferedSoldType
2009-08-12Indefinite$0Option to Acquire, Security to be Acquired
2008-05-14Unknown Unknown Other (Paper Filing)

Key Executives

  • Robert E. Conway
    Executive Officer, Director
  • R. Michael Carruthers
    Executive Officer
  • David Snitnam
    Executive Officer, Director
  • Kevin Koch
    Executive Officer, Director
  • John R. Moore
    Executive Officer
  • Marvin H. Caruthers
    Director
  • Francis J. Bullock
    Director
  • Kyle A. Lefkoff
    Director
  • Douglas E. Williams
    Director
  • Gil J. Van Lunsen
    Director
  • John L. Zabriskie
    Director